Education
About Us
Working with TipRanks
Follow Us
Alterity Therapeutics (ATHE)
:ATHE
ATHE Stock Chart & Stats
$3.55
-$0.16(-4.23%)
At close: 4:00 PM EST
$3.55
-$0.16(-4.23%)
Day’s Range― - ―
52-Week Range$1.41 - $7.00
Previous CloseN/A
Volume131.33K
Average Volume (3M)18.06K
Market Cap
$70.89M
Enterprise Value$26.57M
Total Cash (Recent Filing)$40.66M
Total Debt (Recent Filing)$155.46K
Price to Earnings (P/E)―
Beta1.13
Next Earnings
Feb 26, 2026EPS Estimate
-0.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.52
Shares Outstanding18,125,694
10 Day Avg. Volume10,716
30 Day Avg. Volume18,060
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)1.56
Price to Sales (P/S)12.18
P/FCF Ratio-5.79
Enterprise Value/Market Cap0.37
Enterprise Value/Revenue4.88
Enterprise Value/Gross Profit5.00
Enterprise Value/Ebitda-1.82
Forecast
1Y Price Target
$12.00Price Target Upside238.03% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.03
Revenue Forecast (FY)$5.31M
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessAlterity announced the presentation of positive data from its Phase 2 in Multiple System Atrophy (MSA) at the 2025 International Congress of Parkinson’s Disease and Movement Disorders.
Drug EfficacyATH434 demonstrated a beneficial effect on orthostatic hypotension, with stabilization from baseline in both the 50mg and 75mg groups compared to a 6-point decline over 52 weeks for placebo.
Safety ProfileThe drug was also well tolerated with no treatment-related serious adverse events.
Bears Say
Alterity Therapeutics News
ATHE FAQ
What was Alterity Therapeutics’s price range in the past 12 months?
Alterity Therapeutics lowest stock price was $1.41 and its highest was $7.00 in the past 12 months.
What is Alterity Therapeutics’s market cap?
Alterity Therapeutics’s market cap is $70.89M.
When is Alterity Therapeutics’s upcoming earnings report date?
Alterity Therapeutics’s upcoming earnings report date is Feb 26, 2026 which is in 87 days.
How were Alterity Therapeutics’s earnings last quarter?
Alterity Therapeutics released its earnings results on Feb 28, 2025. The company reported -$0.522 earnings per share for the quarter, missing the consensus estimate of -$0.163 by -$0.359.
Is Alterity Therapeutics overvalued?
According to Wall Street analysts Alterity Therapeutics’s price is currently Undervalued.
Does Alterity Therapeutics pay dividends?
Alterity Therapeutics does not currently pay dividends.
What is Alterity Therapeutics’s EPS estimate?
Alterity Therapeutics’s EPS estimate is -0.47.
How many shares outstanding does Alterity Therapeutics have?
Alterity Therapeutics has 18,125,694 shares outstanding.
What happened to Alterity Therapeutics’s price movement after its last earnings report?
Alterity Therapeutics reported an EPS of -$0.522 in its last earnings report, missing expectations of -$0.163. Following the earnings report the stock price went down -2.326%.
Which hedge fund is a major shareholder of Alterity Therapeutics?
Currently, no hedge funds are holding shares in ATHE
Alterity Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
230.27%
12-Months-Change
Fundamentals
Return on Equity
-42.68%
Trailing 12-Months
Asset Growth
134.94%
Trailing 12-Months
Company Description
Alterity Therapeutics
Alterity Therapeutics (ATHE) is a biotechnology company focused on developing innovative therapies for neurodegenerative diseases, particularly in the realm of protein misfolding disorders. The company operates primarily in the healthcare sector, leveraging its proprietary drug development platform to create novel treatments aimed at addressing unmet medical needs in conditions such as Alzheimer's disease and Parkinson's disease. Alterity's core pipeline includes drug candidates that target specific molecular mechanisms involved in these disorders, with the goal of improving patient outcomes and quality of life.
ATHE Stock 12 Month Forecast
Average Price Target
$12.00
▲(238.03% Upside)
Technical Analysis
Cel-Sci
―
XBiotech
―
Repare Therapeutics
―
Kalaris Therapeutics
―
Unicycive Therapeutics
―
Ownership Overview
―
Insiders
<0.01% Mutual Funds
1.27% Other Institutional Investors
98.73% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---